Aptose Biosciences Inc

NASDAQ:APTOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

View on Canadian Exchange

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Contact Information

Headquarters

251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3

Phone

647-479-9828

Fax

416-798-2200

Executives

Chairman of the Board, President, Chief Executive Officer

William Rice

Chief Financial Officer, Senior Vice President, Chief Business Officer

Fletcher Payne

Senior Vice President, Chief Medical Officer

Rafael Bejar

Senior Vice President, Chief Commercial Officer

Philippe Ledru

Lead Independent Director

Denis Burger